On December 5, 2016, we visited the National Institutes of Health for a conversation with Dr. Richard Hodes, director of the National Institute on Aging (NIA), about public and private efforts being made to advance Alzheimer's research.
Find out about the exciting progress being made with gamma secretase modulators, a potential drug therapy for Alzheimer’s, in this one-hour webinar. Steven Wagner, Ph.D., principal investigator at UC San Diego's Department of Neuroscience, talks to David Shenk, senior adviser, Cure Alzheimer's Fund, about how the modulators work and what’s being done to get them to human trials. This webinar was recorded at our annual Research Consortium meeting in San Diego.
Genes to Therapies™ is the next phase of Cure Alzheimer’s Fund’s long-term plan for attacking Alzheimer’s disease from every possible angle. After locating nearly 100 gene variants that impact Alzheimer’s risk, researchers now plan to investigate the precise function of each gene, the consequence of each variant and precisely how to intervene to arrest the disease process.
On Dec. 16, Dr. David Holtzman of Washington University spoke about his work on the connection between sleep and Alzheimer’s disease, and sleep’s possible role in managing the brain’s Abeta and tau burdens.